- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
HHS Stands Behind Final Rules on Interoperability of Patient Data
Patients should have final say and control over their health data, HHS said Tuesday.
Trump administration officials Tuesday said they won’t be deterred by some industry opposition to their plan to move forward with rules to modernize patient data, make it portable, and create interoperability.
At the second day of the Academy Health combined National Health Policy Conference and Health Datapalooza, HHS Secretary Alex Azar and Don Rucker, the department’s national coordinator for health information technology in the Office of the National Coordinator for Health IT (ONC), said the issue of who should be in control of patient data is about access and choice.
The release of final interoperability and patient information access rules from Rucker’s office is expected shortly. The rules seek to end information blocking and give patients more control and choice over their data.
“Patients should be able to access their electronic medical record at no cost, period,” said Azar. “Providers should be able to use the IT tools that allow them to provide the best care for patients, without excessive costs or technical barriers.”
Last month, Epic, the nation’s largest provider of electronic health record (EHR) software, asked that the rules be delayed, saying that patient privacy is at stake.
“Unfortunately, defenders of the balkanized, outdated status quo have fought our proposals fiercely,” Azar said. “Scare tactics are not going to stop the reforms that we need.”
Following Azar’s appearance, Rucker was asked by Lisa Simpson, MB, BCh, MPH, president and chief executive officer of AcademyHealth, if he thought the privacy concerns are real.
Although privacy is a huge issue, he said, most people love the convenience of modern computing power contained in their smartphones. “I think when the rule comes out you’re going to see some pretty solid protections,” he said.
Regardless, he said, it's the patient who should have final say over their data—the rule does not mean that they have to do anything with it or take advantge of any options..
The issue of patient choice makes sense when one is not sick, Simpson said, but Rucker disagreed with that point.
"You can make healthcare decisions before you’re in extremis," he said.
The Push for Fair Pricing and Reform in Pharmacy Benefit Management
April 3rd 2025Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to enhance transparency, reduce patient costs, and navigate the evolving healthcare landscape.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Using AI-Driven Strategies to Optimize Specialty Drug Costs, Manage Polypharmacy
April 2nd 2025As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More
The IRA’s Unintended Consequences for Drug Pricing and Coverage
April 2nd 2025The Inflation Reduction Act (IRA) may be restricting Medicare Part D formularies, increasing patient costs, and stifling pharmaceutical innovation, experts warned at the Academy of Managed Care Pharmacy 2025 annual meeting.
Read More
